Incyte's stock sinks as pivotal skin disease data disappoint
Incyte’s topline pivotal data for its oral therapy for a painful inflammatory skin condition appear somewhat disappointing, with efficacy falling short of analysts’ expectations and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.